Blog Details
In the early 2000s, industrial policy incentives for Himachal Pradesh triggered a wave of pharmaceutical investment into Baddi. Companies came for the incentives — but they stayed for what developed around them: a complete manufacturing ecosystem. Today the belt hosts hundreds of drug manufacturing units, and India as a whole accounts for approximately 3,000 WHO-GMP approved plants — the largest such concentration outside the United States.
The state drug administration in Himachal Pradesh oversees one of India’s densest concentrations of pharmaceutical units, and the inspection and licensing machinery is correspondingly experienced. Approvals, renewals, and certifications follow well-worn processes — our own WHO-GMP certification and manufacturing licenses (valid through 2029) are issued and renewed through this system.
Baddi offers competitive manufacturing costs — but the meaningful point is what the cost buys. India supplies around 50% of global demand for various generic medicines precisely because it combines cost advantage with internationally accepted quality standards. Baddi is that combination, concentrated in one valley.
Recent Posts
A Leader in World-Class Pharmaceutical Manufacturing and Social Service A Powerful Confluence of Industry
Third-Party vs. Contract Manufacturing: Which Model Fits Your Brand?
Inside Baddi: Why India’s Pharma Heartland Is the Smart Manufacturing Choice